Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2026 15:34 ET | Source: Cosmos Health Inc.

CosmoFarm Delivers Record Q2 2026 Revenue of Over $15M, Representing $60+ Million Annualized Run-Rate; Adds Over 80 Pharmacies and Expands AI Automation and Facility Capacity

CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its...
June 17, 2026 15:35 ET | Source: Cosmos Health Inc.

Cosmos Health Enters the $163 Billion Global Skincare Market; Sales Already Underway in the United States

Cosmos Health enters the global skincare market. Sales already underway in the United States.
June 17, 2026 09:27 ET | Source: Cosmos Health Inc.

Cosmos Health Signs 2.86 Million-Unit Contract Manufacturing Agreement With Pharmex S.A. Across Three Dermatological Products

Cosmos Health signs 1.72 million-unit contract manufacturing agreement With Pharmex S.A. across three dermatological products.
June 15, 2026 09:00 ET | Source: Cosmos Health Inc.

Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit

Cosmos Health provides update on United States portfolio.
June 12, 2026 15:33 ET | Source: Cosmos Health Inc.

Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines

Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines
June 12, 2026 09:29 ET | Source: Cosmos Health Inc.

Cosmos Health Reports Annualized Sales Exceeding $1.5M for Its C-Scrub and C-Sept Antiseptic Brands in the UK and Greece; Plans EU Expansion Targeting $7.4M in Revenue and $5.3M in Gross Profit

Cosmos Health announces strong sales momentum for its proprietary antiseptic brands, C-Scrub and C-Sept.
June 11, 2026 15:31 ET | Source: Cosmos Health Inc.

Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio

Cosmos Health signs LOI to acquire Doc Pharma S.A.
June 11, 2026 09:35 ET | Source: Cosmos Health Inc.

Cosmos Health Secures Additional 180-Day Nasdaq Extension to Regain Bid Price Compliance

Cosmos Health secures additional 180-day Nasdaq extension to regain compliance.
June 10, 2026 15:32 ET | Source: Cosmos Health Inc.

Cosmos Health Signs 3-Year Contract Manufacturing Agreement with Verisfield for 3.9 Million Units of VASCLOR GEST Progesterone Pessaries

Cosmos Health secures a 3-year contract manufacturing agreement for 3.9 million units of VASCLOR GEST progesterone pessaries.
June 10, 2026 09:00 ET | Source: Cosmos Health Inc.

Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway

Cosmos Health CEO issues letter to shareholders.